ロード中...
Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group
Data on efficacy and safety of azacitidine in acute myeloid leukemia (AML) with >30 % bone marrow (BM) blasts are limited, and the drug can only be used off-label in these patients. We previously reported on the efficacy and safety of azacitidine in 155 AML patients treated within the Austrian Az...
保存先:
| 主要な著者: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer Berlin Heidelberg
2014
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4176957/ https://ncbi.nlm.nih.gov/pubmed/24951123 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-014-2126-9 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|